BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cacabelos R. Pharmacogenomics of drugs used to treat brain disorders. Expert Review of Precision Medicine and Drug Development 2020;5:181-234. [DOI: 10.1080/23808993.2020.1738217] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Cacabelos R, Naidoo V, Martínez-iglesias O, Corzo L, Cacabelos N, Pego R, Carril JC. Personalized Management and Treatment of Alzheimer’s Disease. Life 2022;12:460. [DOI: 10.3390/life12030460] [Reference Citation Analysis]
2 Cacabelos R. What have we learnt from past failures in Alzheimer's disease drug discovery? Expert Opin Drug Discov 2022;:1-15. [PMID: 35129021 DOI: 10.1080/17460441.2022.2033724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cacabelos R, Naidoo V, Martínez-iglesias O, Corzo L, Cacabelos N, Pego R, Carril JC. Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development. Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2573-6_13] [Reference Citation Analysis]
4 Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. IJMS 2021;22:13302. [DOI: 10.3390/ijms222413302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Pardiñas AF, Owen MJ, Walters JTR. Pharmacogenomics: A road ahead for precision medicine in psychiatry. Neuron 2021:S0896-6273(21)00683-8. [PMID: 34619094 DOI: 10.1016/j.neuron.2021.09.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
6 Cacabelos R, Carrera I, Martínez O, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, Rodríguez S, Alcaraz M, Nebril L, Tellado I, Cacabelos N, Pego R, Naidoo V, Carril JC. Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. Med Res Rev 2021;41:2841-86. [PMID: 34106485 DOI: 10.1002/med.21838] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Alexander RT, Langdon PE, O'Hara J, Howell A, Lane T, Tharian R, Shankar R. Psychiatry and neurodevelopmental disorders: experts by experience, clinical care and research. Br J Psychiatry 2021;218:1-3. [PMID: 33541475 DOI: 10.1192/bjp.2020.237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Cacabelos R, Carrera I, Martínez O, Naidoo V, Cacabelos N, Aliev G, Carril JC. Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson's disease. Drug Dev Res 2021;82:695-706. [PMID: 33458869 DOI: 10.1002/ddr.21784] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Cacabelos R. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease. Expert Opin Drug Metab Toxicol 2020;16:673-701. [PMID: 32520597 DOI: 10.1080/17425255.2020.1779700] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]